WASHINGTON (Reuters) - U.S. lawmakers on Wednesday blasted steep price increases for Mylan's EpiPen emergency allergy treatment as they grilled the company's Chief Executive Heather Bresch at a congressional hearing. The House Committee on Oversight and Government Reform called Bresch to testify after the company raised the list price for a pair of EpiPens to $600 compared with $100 in 2007, when it acquired the product.
Read more
No comments:
Post a Comment